C.H. Robinson falls 10.8% after announcement of RXO acquisition

What happened

C.H. Robinson (CHRW) fell 10.8% on October 5, 2026, after the company agreed to acquire RXO in a cash-and-stock transaction valued at $5.8 billion, a deal management said would be accretive to earnings in under a year. The announcement specified that RXO shareholders would receive $17.25 in cash plus 0.0856 shares of C.H. Robinson common stock per RXO share, implying $30.25 per RXO share, according to The Motley Fool and Defense World. Management said it expected $300 million in annual cost savings from the transaction.

How big was the move

The stock fell 10.8% on the session, a move equal to 3.1 times a typical daily move for this stock and 10.8 percentage points worse than the Industrials sector median, which fell 0.1% on the day. Trading volume was 6.0 times its 20-day average, signalling unusually heavy activity. The S&P 500 rose 0.7% on the day, and over the last five sessions the stock fell 5.1% while the S&P 500 rose 1.2%, underlining that the move was largely company-specific. The stock’s market sensitivity, a beta of 0.92, indicates it tends to move about as much as the market, but this decline far outpaced benchmark moves.

The technical picture

The stock closed at $140.61, 7.0% below its 20-day moving average and 6.5% below its 50-day moving average. The 50-day average is below the 200-day average, a sign of a weak longer-term trend, and the stock sits 18.4% below its 200-day moving average. Its Relative Strength Index (14 days) was 38, inside a neutral range between 30 and 70. Shares were 33.1% below the 52-week high and over three months they fell 26.4%, while they rose 4.3% over one year, which left the stock 11.4 percentage points behind the S&P 500.

Volatility was elevated: annualized over 60 days it measured 56%, the highest reading of the past five years. That combination of a sharp, news-driven drop and unusually high volume often leads to outsized short-term price swings as investors assess deal terms and integration risk.

Fundamentals and valuation

On the four quarters through June 30, 2026, revenue was $17.00 billion, a decline of 0.1% from a year earlier. Diluted earnings per share for that period were $5.24, up 19.4% from a year earlier. Gross margin was 10.1%, versus 8.1% a year earlier, and operating margin was 4.9%, versus 4.4% a year earlier. Free-cash-flow margin was 3.9%, and return on invested capital was 18.6%. The balance sheet shows net debt of 1.8 times EBITDA, and share count over one year decreased by 1.4%.

Valuation metrics show the stock trading at 26.8 times trailing earnings and 22.5 times expected forward earnings, with a free-cash-flow yield of 3.6%. Its price to trailing earnings was higher than 67% of its own readings over the past five years, where the five-year median stood at 25.1 times earnings. PromtFinance scores rank the company Neutral on Value at 61 and Positive on Revisions at 74, while Growth, Quality, Momentum and Stability show weaker readings.

Those measures suggested investors were paying a premium for earnings visibility and cash generation before the deal. The transaction will add complexity to the valuation picture: management expects $300 million in annual cost savings, but investors must weigh integration risk and the impact of additional shares issued under the exchange ratio on per-share metrics.

Earnings and analyst expectations

C.H. Robinson last reported on July 29, 2026, delivering earnings per share of $1.61 against $1.53 expected, 5.2% above estimates. The company had beaten estimates in 10 consecutive quarters, with an average surprise over the last four reports of 8.1% above estimates. Typical two-day reactions after recent reports have seen the stock rise 0.5%.

Analysts covering the stock numbered 46, with a consensus rating of Buy and 50% of those ratings at Buy. The consensus price target was $194.50, 38.3% above the closing price. The next report was scheduled for November 4, 2026, a date investors will watch closely for any changes to guidance or comments about the RXO deal and expected accretion.

What to watch

• The integration plan and timing for the RXO acquisition and any regulatory filings or approvals tied to the transaction.
• Any updates from management on the $300 million in annual cost savings and the schedule for achieving accretion to earnings.
• Trading volume and price reaction in the days after October 5, 2026, with attention to whether volatility moderates from 56% annualized over 60 days.
• The company’s Nov. 4, 2026, earnings report and any guidance changes tied to the acquisition.
• Changes in analyst estimates or the consensus price target of $194.50 following deal-related disclosures.